Skip to main content
In stock|Immunotherapy (Checkpoint Inhibitor)

Cosibelimab

Oncology TypeSolid Tumour
Drug Class / MechanismAnti-PD-L1 Monoclonal Antibody
No Image
Description

Cosibelimab is classified as an Anti-PD-L1 Monoclonal Antibody, sourced for use within our Immunotherapy (Checkpoint Inhibitor) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryImmunotherapy (Checkpoint Inhibitor)
Oncology TypeSolid Tumour

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3